How to Get Evenity (Romosozumab) in Arkansas

What Evenity (Romosozumab) Does and Why Arkansas Patients Seek It

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, the drug simultaneously stimulates new bone growth and reduces bone resorption, a dual mechanism no other osteoporosis therapy replicates.

The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of other osteoporosis therapies (FDA label). Arkansas ranks among the states with the highest hip fracture rates in women over 65, according to CDC surveillance data (CDC osteoporosis data). That epidemiologic burden drives demand for romosozumab access across the state, particularly in rural counties where specialty care is limited.

The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk reduction) compared with alendronate alone (Saag KG et al., NEJM 2017). A separate phase 3 trial, FRAME (N=7,180), demonstrated that romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months (Cosman F et al., NEJM 2016). These results establish romosozumab as the most potent anabolic agent currently available for osteoporosis.

Step-by-Step: Getting a Romosozumab Prescription in Arkansas

The prescription pathway begins with a bone density evaluation and clinical risk assessment, then moves through prior authorization before the first injection can be scheduled.

Step 1: Clinical evaluation. A prescriber orders a DXA scan and reviews fracture history. Romosozumab is appropriate when the T-score is <-2.5 at the spine or hip, or when the patient has sustained a fragility fracture despite existing therapy. The American Association of Clinical Endocrinology (AACE) 2020 guidelines classify these patients as "very high risk" and recommend anabolic-first treatment sequencing (AACE 2020 guidelines).

Step 2: Cardiovascular screening. The Evenity label carries a black box warning for increased risk of myocardial infarction, stroke, and cardiovascular death. Prescribers must confirm no MI or stroke within the preceding 12 months. A baseline cardiovascular risk assessment, including blood pressure and lipid panel review, is standard before initiating therapy.

Step 3: Prior authorization submission. The prescriber's office submits a PA request to the patient's insurer. Required documentation typically includes the DXA report, fracture history, documentation of prior therapy failure or intolerance, and cardiovascular clearance.

Step 4: Specialty pharmacy fulfillment. Once approved, the insurer routes the prescription to a preferred specialty pharmacy. The patient or clinic receives the two prefilled syringes for the first monthly dose.

Step 5: Administration. The injections are given subcutaneously in the abdomen, thigh, or upper arm. Most patients receive them in a clinic setting, although self-administration at home is permitted after proper training.

Telehealth Access to Evenity in Arkansas

Arkansas permits telehealth prescribing for romosozumab, making it possible for patients in underserved areas to consult a specialist without a multi-hour drive to Little Rock, Fayetteville, or Jonesboro.

Arkansas Act 203 (2021) established a permanent telehealth framework that allows physicians, nurse practitioners, and physician assistants licensed in the state to prescribe medications via audio-video visits. The prescriber must hold an active Arkansas medical license or be registered through the Interstate Medical Licensure Compact. Arkansas joined the Compact in 2017, which expands the pool of specialists available to state residents (Federation of State Medical Boards, IMLC).

A telehealth consultation for romosozumab typically follows this sequence: the patient uploads recent DXA results and lab work, the provider conducts a video visit to review fracture risk and cardiovascular history, and the provider submits the PA electronically. The injection itself can be administered at a local clinic, infusion center, or at home if the patient is trained. This model is especially valuable in the Arkansas Delta region, where the nearest endocrinologist may be 90 or more miles away.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and principal investigator on multiple romosozumab trials, has stated: "The treat-to-target approach in osteoporosis means starting with the most effective agent first, not saving it for last. Romosozumab followed by a potent antiresorptive gives patients the best chance of reaching a fracture-resistant bone density." This sequencing philosophy aligns with the AACE recommendation to initiate anabolic therapy before transitioning to antiresorptives like denosumab or zoledronic acid.

Arkansas Medicaid and Insurance Coverage

Arkansas Medicaid covers Evenity on a limited basis with prior authorization, primarily for patients with severe osteoporosis who meet specific clinical criteria.

The Arkansas Department of Human Services Medicaid pharmacy program classifies romosozumab as a specialty drug requiring step therapy documentation. In practice, this means the patient must have tried and failed (or be intolerant to) at least one first-line agent, typically alendronate or risedronate, before Medicaid will approve Evenity. Documentation of a T-score at or below -2.5 and at least one prior fragility fracture significantly strengthens the PA request.

For commercial insurers operating in Arkansas (Blue Cross Blue Shield of Arkansas, QualChoice, Ambetter, United Healthcare), coverage policies vary but follow a similar pattern. Most require:

• DXA-confirmed osteoporosis (T-score ≤ -2.5)
• At least one prior fragility fracture, OR failure/intolerance of oral bisphosphonates
• Cardiovascular clearance documentation
• Prescriber is a specialist (endocrinologist, rheumatologist, or orthopedic surgeon) or has documented specialist consultation

The Amgen Assist 360 program offers co-pay assistance for commercially insured patients, reducing out-of-pocket costs to as little as $5 per month for eligible individuals. For uninsured patients, Amgen's Safety Net Foundation may provide Evenity at no cost if household income falls below 300% of the federal poverty level (Amgen patient assistance).

Average PA turnaround in Arkansas ranges from 5 to 14 business days. Peer-to-peer review requests, where the prescriber speaks directly with the insurer's medical director, can resolve denials more quickly than written appeals.

Required Labs Before Starting Evenity in Arkansas

A baseline lab panel confirms eligibility and establishes monitoring benchmarks before the first romosozumab injection.

The minimum lab panel includes serum calcium (corrected for albumin), 25-hydroxyvitamin D, serum creatinine with eGFR, and a complete metabolic panel. Hypocalcemia must be corrected before initiating romosozumab, as the drug can further lower serum calcium. The Endocrine Society recommends a minimum 25-hydroxyvitamin D level of 20 ng/mL, though many clinicians target 30 ng/mL or above before starting any anabolic agent (Endocrine Society vitamin D guidelines).

Bone turnover markers, specifically serum P1NP (procollagen type 1 N-terminal propeptide) and CTX (C-terminal telopeptide), are not required but provide useful baseline data. P1NP rises sharply within the first month of romosozumab therapy and peaks around month 6. Tracking this marker helps confirm the drug is producing its expected anabolic effect.

Cardiac workup depends on the patient's baseline risk. For women over 65, a resting ECG and lipid panel are reasonable additions. Patients with diabetes, hypertension, or a 10-year ASCVD risk score above 15% may need cardiology clearance before the prescriber will submit the PA.

Labs can be drawn at any Quest, UAMS, or hospital-affiliated lab across Arkansas. Results are typically available within 48 hours and can be uploaded to a telehealth portal if the patient is working with a remote specialist.

Who Can Prescribe Romosozumab in Arkansas

Arkansas law permits MDs, DOs, nurse practitioners, and physician assistants to prescribe romosozumab, though insurer policies sometimes restrict coverage to specialist prescribers.

Physicians (MD/DO) with any active Arkansas license can prescribe Evenity without restriction. This includes primary care physicians, although most commercial PA forms ask whether a specialist was consulted. Having an endocrinologist or rheumatologist listed as the prescribing or consulting provider reduces PA friction considerably.

Nurse practitioners in Arkansas practice under a collaborative practice agreement with a physician. NPs with prescriptive authority can prescribe romosozumab, and Arkansas Medicaid accepts NP-written prescriptions for specialty drugs as long as the collaborative agreement is on file. The 2021 APRN Practice Act did not grant full practice authority to NPs in Arkansas, so the collaborative requirement remains in effect.

Physician assistants prescribe under their supervising physician's license. The supervising physician does not need to be physically present for the prescription to be valid, but the PA relationship must be documented. Some insurers require the supervising physician's NPI on the PA form rather than the PA's NPI.

The Endocrine Society's 2020 position paper on osteoporosis management noted: "Given the complexity of sequential osteoporosis therapy, initiation of romosozumab is best managed by clinicians with expertise in metabolic bone disease" (Endocrine Society guidelines).

Pharmacy and Fulfillment Options in Arkansas

Evenity is a specialty medication distributed through a closed pharmacy network, meaning standard retail pharmacies like Walgreens or CVS do not stock it.

Amgen's distribution model routes Evenity through specialty pharmacies partnered with the patient's insurer. Common specialty pharmacy partners include Accredo (Express Scripts), OptumRx Specialty, CVS Specialty, and Biologics by McKesson. The insurer's PA approval letter specifies which specialty pharmacy will fill the prescription.

Arkansas-licensed 503A compounding pharmacies operate in the state, but romosozumab is a biologic monoclonal antibody that cannot be compounded. It is produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells, a process exclusive to the manufacturer's facilities. Patients should be wary of any pharmacy claiming to compound or provide a "generic" romosozumab. No biosimilar exists as of mid-2026.

Specialty pharmacy shipment to Arkansas addresses typically takes 3 to 7 business days after PA approval. The medication ships in cold packs (2°C to 8°C) via overnight or two-day courier. Patients in rural ZIP codes should confirm that someone will be available to receive the package, as the drug cannot sit on a porch in Arkansas summer heat.

For patients who prefer clinic-administered injections, the specialty pharmacy can ship directly to the treating physician's office. Many endocrinology and rheumatology clinics in Little Rock, Fayetteville, Fort Smith, and Jonesboro have refrigerated storage for biologics and can administer the monthly injections on site.

Timeline: From First Visit to First Injection in Arkansas

Most Arkansas patients can expect 3 to 6 weeks between their initial consultation and the first romosozumab injection, assuming no PA complications.

Here is a realistic timeline breakdown:

• Week 1: Initial visit (in person or telehealth). DXA scan ordered if not done within the past 24 months. Labs drawn.
• Week 2: Lab results reviewed. Prescriber determines eligibility and submits PA to insurer.
• Weeks 2 to 4: PA review period. Average commercial insurer turnaround is 7 to 10 business days. Medicaid may take up to 14 business days. If denied, a peer-to-peer review adds 3 to 5 days.
• Week 4 to 5: PA approved. Specialty pharmacy receives the prescription and ships the first dose.
• Week 5 to 6: First injection administered.

The ARCH trial protocol initiated romosozumab within 14 days of screening (Saag KG et al., NEJM 2017). Clinical trial timelines are faster than real-world access because PA is not involved. Patients with recent vertebral fractures should ask their prescriber about expedited or urgent PA pathways, as some insurers offer 24 to 72-hour turnaround for acute fracture cases.

After the first dose, the remaining 11 monthly injections follow a predictable schedule. Patients should transition to an antiresorptive (denosumab or zoledronic acid) immediately after completing the 12-month romosozumab course. Delaying the transition allows rapid bone density loss, as demonstrated in the FRAME extension study where patients who received placebo after romosozumab lost a significant portion of gains within 12 months (Cosman F et al., JBMR 2018).

Cost Breakdown and Financial Assistance

The wholesale acquisition cost (WAC) of Evenity is approximately $1,825 per monthly dose, bringing the full 12-month course to roughly $21,900 before insurance.

With commercial insurance and Amgen's co-pay card, most patients pay $5 to $50 per month. Medicare Part B covers Evenity under the medical benefit (not Part D) when administered in a physician's office, with patients responsible for the 20% coinsurance after meeting the Part B deductible. A Medigap or Medicare Supplement plan covers most or all of that 20%.

Arkansas Medicaid pays a negotiated rate that is significantly below WAC. Patient cost-sharing under Arkansas Medicaid is minimal, typically $0 to $3 per prescription.

For uninsured patients, the Amgen Safety Net Foundation and independent foundations like the HealthWell Foundation and Patient Advocate Foundation offer grants that can cover the full cost. Application processing takes 5 to 10 business days.

The 12-dose treatment limit is both a clinical and financial boundary. Romosozumab's anabolic effect diminishes after 12 months as anti-drug antibodies and sclerostin rebound blunt the response. There is currently no clinical evidence supporting a second course of romosozumab.